- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01337011
Intra-coronary Versus Intramyocardial Application of Enriched CD133pos Autologous Bone Marrow Derived Stem Cells (AlsterMACS)
Pilot Study Comparing the Effect of Intra-coronary Versus Intramyocardial Application of Enriched CD133pos Autologous Bone Marrow Derived Stem Cells for Improving Left Ventricular Function in Chronic Ischemic Cardiomyopathy
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Recent years have seen a tremendous improvement of possibilities to restore normal cardiac perfusion of the coronary arteries both by surgical and interventional techniques. In addition, several pharmacological approaches are available to block the mal-adaptive molecular signaling initiated by the Renin/Angiotensin/Aldosteron (RAAS) system. Device therapy achieving resychronisation has lowered morbidity and mortality. However, heart failure therapy still falls short to address the underlying disease of the heart muscle: loss of contractile force.
To achieve this aim and restore contractile force a regenerative approach is required. Early experimental studies suggested bone marrow cells to be able to differentiate towards functional cardiomyocytes when injected into the scar area after ischemic injury.2 These and other studies lead to clinical trials, where bone marrow cells were injected into the coronary circulation. Lately, the first completed multi-center, placebo-controlled, double-blinded study found several end points to be improved including global left ventricular function 3. At the same time genetically labelled experimental mouse models demonstrated differentiation of bone marrow cells towards a cardiomyocyte lineage to be a rare event,4 questioning at least the proposed molecular and cellular mechanism of intra-coronary cell therapy. Furthermore, several other clinical trials recently performed did either find no or a very limited effect of intra-coronary applied bone marrow cells. The effect appears to be related to improved angiogenesis. Our group has recently shown that in mammals endogenous regeneration of myocardium does occur after injury and can be enhanced via specific signaling pathways.5 Whether intra-coronary cell therapy is the ideal approach to enhance this process is currently unclear.
References:
- Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, Hochadel M, Komajda M, Lassus J, Lopez-Sendon JL, Ponikowski P, Tavazzi L. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006;27:2725-2736.
- Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, Nadal-Ginard B, Bodine DM, Leri A, Anversa P. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A. 2001;98:10344-10349.
- Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Suselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM, the R-AMII. Intracoronary Bone Marrow-Derived Progenitor Cells in Acute Myocardial Infarction. N Engl J Med. 2006;355:1210-1221.
- Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, Pasumarthi KB, Virag JI, Bartelmez SH, Poppa V, Bradford G, Dowell JD, Williams DA, Field LJ. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature. 2004;428:664-668.
- Zelarayan L, Noack C, Sekkali B, Kmecova J, Gehrke C, Renger A, Zafiriou MP, Nagel Rvd, Dietz R, Windt LJd, Balligand J-L, Bergmann MW. beta-catenin downregulation attenuates ischemic cardiac remodeling through enhanced resident precursor cell differentiation. Proc Natl Acad Sci U S A. 2008;105:19762-19767.
- Krause KT, Jaquet K, Geidel S, Schneider C, Mandel C, Stoll HP, Hertting K, Harle T, Kuck KH. Percutaneous endocardial injection of erythropoietin: assessment of cardioprotection by electromechanical mapping. Eur J Heart Fail. 2006;8:443-450.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Hamburg, Tyskland, 20099
- Asklepios Klinik St. Georg
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Patients 18 to 80 years old
- Of female and male gender
- Patient has reduced ejection fraction as evaluated by routine clinical angiogram, echocardiography or MRI (≤45%) due to ischemic heart disease
- symptomatic heart failure NYHA ≥ II on optimal therapy
- coronary artery in the target region that can be used for cell infusion
- Patient has been informed of the nature of the clinical trial and agrees to its provision and has provided written informed consent
Exclusion Criteria:
- planned or performed CABG surgery or PCI within 4 weeks of study entry
- recent myocardial infarction (< 6 months)
- TIMI flow < II in the coronary artery selected for infusion
- cardiogenic shock requiring mechanical ventilation or intra-aortic balloon pump
- progressive tumor disease
- primary disease of bone marrow including mal-function of components of the coagulation system
- women of child-bearing age premenopausal
- LV wall thickness < 5mm at planned site of injection
- ventricular wall thrombus
- severe aortic valvular heart disease
- severe atrial or ventricular tachycardia unresponsive to intravenous or oral drug therapy
- aneurysm of the anterior wall
- history of stroke
- know diseases of the liver resulting in reduced plasmatic coagulation with spontaneous INR >2
- patients with chronic infectious diseases (HBV, HCV, HIV, seropositivity for Treponema pallidum)
- patients taking part or have taken part in other clinical trials within the past 3 months
- patients unable to provide informed consent
- any other medical condition that the enrolling physician deems significant in representing a potential hazard for the patient when participating in this study
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: intra-coronary administration
Application of stem cells using the intra-coronary route.
|
The study aims to show efficacy of both intra-myocardial autologous CD133pos bone marrow cell application as well as intra-coronary CD133pos cell application in patients with symptomatic ischemic heart disease.
In addition, efficacy between the two delivery routes will be compared.
|
Experimentell: intra-myocardial administration
Application of stem cells using the intra-myocardial route.
|
The study aims to show efficacy of both intra-myocardial autologous CD133pos bone marrow cell application as well as intra-coronary CD133pos cell application in patients with symptomatic ischemic heart disease.
In addition, efficacy between the two delivery routes will be compared.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
LVEF
Tidsram: after 6 to 12 months
|
Improvement of global left ventricular function as well as global strain rate as assessed by echocardiography.
Transthoracic echocardiography will be performed at baseline and after 6 and 12 month.
Images are acquired in the standard parasternal and apical views.
|
after 6 to 12 months
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Martin Bergmann, PD Dr., Asklepios Kliniken Hamburg GmbH
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 1884
- 2009-013103-63 (EudraCT-nummer)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Hjärtsvikt
-
Region SkaneAnmälan via inbjudanHjärtsvikt New York Heart Association (NYHA) klass II | Hjärtsvikt New York Heart Association (NYHA) klass IIISverige
-
Taichung Veterans General HospitalRekryteringKontinuerlig Fetal Heart Beat Monitor och analys efter Spinal AnestesiTaiwan
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan... och andra samarbetspartnersHar inte rekryterat ännuHjärtsvikt, systolisk | Hjärtsvikt Med Minskad Ejection Fraktion | Hjärtsvikt New York Heart Association Klass IV | Hjärtsvikt New York Heart Association Klass IIIPolen
-
University of WashingtonAmerican Heart AssociationAvslutadHjärtsvikt, Kongestiv | Mitokondriell förändring | Hjärtsvikt New York Heart Association Klass IVFörenta staterna
-
Novartis PharmaceuticalsAvslutadPatienter som framgångsrikt slutfört den 12 månader långa behandlingsperioden i kärnstudien (de Novo Heart Recipients) som var intresserade av att bli behandlad med EC-MPS
-
University Hospital, GasthuisbergOkändTransient Left Ventricular Ballooning SyndromeBelgien
-
Children's Hospital Medical Center, CincinnatiRekryteringNationellt samarbete för att förbättra vården av barn med komplexa medfödda hjärtsjukdomar (NPC-QIC)Hypoplastiskt Left Heart Syndrome (HLHS)Förenta staterna, Storbritannien, Kanada
-
Lifetech Scientific (Shenzhen) Co., Ltd.OkändPatent Ductus Arteriosus | Kanalberoende Cyanotic Congenital Heart DiseaseMalaysia
-
Mayo ClinicRekryteringHypoplastiskt Left Heart Syndrome (HLHS)Förenta staterna
-
NYU Langone HealthRekryteringTako-tsubo kardiomyopati | Takotsubo kardiomyopati | Broken Heart SyndromeFörenta staterna
Kliniska prövningar på autologous CD133pos stem cell application
-
Kimera Society IncAvslutadKronisk obstruktiv lungsjukdomFörenta staterna
-
JKastrupEuropean UnionAvslutad
-
CliPS Co., LtdAvslutadLimbus Corneae insufficienssyndrom | Limbus CorneaeKorea, Republiken av
-
Avita MedicalBiomedical Advanced Research and Development AuthorityAvslutadBrännskadorFörenta staterna
-
Gradalis, Inc.Roche-GenentechAvslutadLivmoderhalscancer | Äggstockscancer | Livmodercancer | Avancerad gynekologisk cancerFörenta staterna
-
Gradalis, Inc.Avslutad
-
Gradalis, Inc.AvslutadSteg IV äggstockscancer | Steg III äggstockscancerFörenta staterna
-
Gradalis, Inc.AvslutadSteg IV äggstockscancer | Steg III äggstockscancerFörenta staterna
-
Gradalis, Inc.AvslutadSarkom | Neoplasmer | Neoplasmer, bindväv och mjukvävnad | Neoplasmer efter histologisk typ | Sarkom, Ewing | Neoplasmer, benvävnad | Neoplasmer, bindväv | Ewing Sarkom | Sällsynta sjukdomar | Ewings tumör metastaserad | Ewing familj av tumörer | Ewings sarkom Metastaserande | Ewings tumör återkommandeFörenta staterna
-
University of California, San FranciscoAvslutadDystoniFörenta staterna